Abstract
We report on a patient with phenylketonuria who developed disabling extrapyramidal features that were successfully controlled with L-dopa. We recommend that all such patients are given a trial with this drug.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Curtius H. C., Baerlocher K., Völlmin J. A. Pathogenesis of phenylketonuria: inhibition of DOPA and catecholamine synthesis in patients with phenylketonuria. Clin Chim Acta. 1972 Nov;42(1):235–239. doi: 10.1016/0009-8981(72)90406-8. [DOI] [PubMed] [Google Scholar]
- FARQUHAR J. W., RICHMOND J., TAIT H. P. PHENYLKETONURIA IN PEDIATRIC PRACTICE. Clin Pediatr (Phila) 1963 Sep;2:504–516. doi: 10.1177/000992286300200908. [DOI] [PubMed] [Google Scholar]
- PAINE R. S. The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria). Pediatrics. 1957 Aug;20(2):290–302. [PubMed] [Google Scholar]